X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6) 6
index medicus (6) 6
hepatoma (5) 5
liver cancer (5) 5
niacinamide - analogs & derivatives (5) 5
antineoplastic agents (4) 4
antineoplastic agents - therapeutic use (4) 4
cancer (4) 4
carcinoma, hepatocellular - drug therapy (4) 4
female (4) 4
liver neoplasms - drug therapy (4) 4
male (4) 4
aged (3) 3
antimitotic agents (3) 3
article (3) 3
carcinoma, hepatocellular - pathology (3) 3
diagnosis (3) 3
liver diseases (3) 3
liver neoplasms - pathology (3) 3
niacinamide - therapeutic use (3) 3
phenylurea compounds - therapeutic use (3) 3
abridged index medicus (2) 2
analysis (2) 2
animals (2) 2
antineoplastic agents - adverse effects (2) 2
cancer therapies (2) 2
care and treatment (2) 2
classification (2) 2
clinical trials (2) 2
colorectal-cancer (2) 2
disease progression (2) 2
double-blind method (2) 2
gastroenterology & hepatology (2) 2
hematology, oncology and palliative medicine (2) 2
hepatitis (2) 2
hepatocellular carcinoma (2) 2
kaplan-meier estimate (2) 2
liver (2) 2
liver cirrhosis (2) 2
management (2) 2
medical colleges (2) 2
medical prognosis (2) 2
medicine (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
mutation (2) 2
oncology (2) 2
phenylurea compounds (2) 2
phenylurea compounds - adverse effects (2) 2
pyridines - therapeutic use (2) 2
research (2) 2
risk-factors (2) 2
signature (2) 2
treatment outcome (2) 2
tumors (2) 2
xenograft model antitumor assays (2) 2
1st-line therapy (1) 1
abdomen (1) 1
accuracy (1) 1
activation (1) 1
adult (1) 1
aged, 80 and over (1) 1
algorithms (1) 1
angiogenesis (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis - drug effects (1) 1
asia (1) 1
australia (1) 1
autophagy (1) 1
b-virus genotype (1) 1
benzenesulfonates - administration & dosage (1) 1
benzenesulfonates - therapeutic use (1) 1
biopsy (1) 1
brivanib (1) 1
cadherins - genetics (1) 1
carboplatin (1) 1
carcinoma (1) 1
carcinoma, hepatocellular - diagnosis (1) 1
carcinoma, hepatocellular - genetics (1) 1
carcinoma, hepatocellular - metabolism (1) 1
carcinoma, hepatocellular - mortality (1) 1
carcinoma, hepatocellular - surgery (1) 1
carcinoma, hepatocellular - therapy (1) 1
catheter ablation - adverse effects (1) 1
catheter ablation - mortality (1) 1
causes of (1) 1
cell line, tumor (1) 1
chemotherapy (1) 1
chemotherapy, adjuvant (1) 1
cisplatin (1) 1
clinical-practice guidelines (1) 1
college teachers (1) 1
càncer de fetge (1) 1
decision making (1) 1
deoxyribonucleic acid--dna (1) 1
digestive system diseases (1) 1
disease-free survival (1) 1
dna methylation (1) 1
drug dosages (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 10, pp. 1386 - 1395
Journal Article
Gut, ISSN 0017-5749, 03/2017, Volume 66, Issue 3, pp. 530 - 540
ObjectiveSorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying... 
molecular genetics | stem cells | Hepatocellular carcinoma | molecular mechanisms | drug resistance | GROWTH-FACTOR RECEPTOR | CLASSIFICATION | ACTIVATION | INHIBITION | GASTROENTEROLOGY & HEPATOLOGY | MUTATION | Niacinamide - analogs & derivatives | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Fibroblast Growth Factors - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Fibroblast Growth Factors - metabolism | Carcinoma, Hepatocellular - drug therapy | Somatomedins - antagonists & inhibitors | Female | Liver Neoplasms - pathology | Spheroids, Cellular | Somatomedins - metabolism | Gene Expression | Signal Transduction | Liver Neoplasms - drug therapy | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Survival Rate | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Disease Progression | Xenograft Model Antitumor Assays | Animals | Receptors, Somatomedin - metabolism | Somatomedins - genetics | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Cell Line, Tumor | Aged | Mice | Mice, Inbred BALB C | Fibroblast Growth Factors - antagonists & inhibitors | Receptors, Somatomedin - antagonists & inhibitors | Carcinoma, Hepatocellular - metabolism | Fibroblast growth factors | Hepatoma | Research | Insulin-like growth factor 1 | Liver cancer | Càncer de fetge | Antineoplastic agents | Medicaments antineoplàstics
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 56, Issue 6, pp. 1343 - 1350
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.